Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation

    NEW YORK, Aug. 20 /EMWNews/ -- Crystal Research Associates, LLC

announced today that it has issued an Executive Informational Overview(R)

(EIO(R)) on Generex Biotechnology Corporation (Nasdaq: GNBT). The full

64-page report can be found at http://www.crystalra.com.



    Generex Biotechnology Corporation ("Generex" or "the Company") is a

specialty pharmaceutical company that aims to research, develop, and

commercialize drug delivery systems and technologies to treat autoimmune

disorders, cancers, and infectious and metabolic diseases. Generex's

RapidMist(TM) platform technology is a device and liquid formulation

combination that can deliver medications to the bloodstream via the buccal

mucosa at an improved absorption rate. This formulation is partially

composed of absorption enhancers, called surfactants, which enable the oral

delivery of a range of compounds, including macromolecules. While the

device's appearance is similar to a pulmonary inhaler, the technology

differs greatly. Traditional inhalers deliver medication into the lungs;

RapidMist(TM) delivers larger-sized molecules into the buccal mucosa of the

mouth, with no lung deposition.



    The Company's lead product, Generex Oral-lyn(TM), is a buccal insulin

spray that uses the RapidMist(TM) platform to treat Type 1 and Type 2

diabetes, which has demonstrated safety and efficacy in clinical trials.

Generex Oral-lyn(TM) is currently approved in Ecuador and India. Generex

has enrolled over 150 patients in a Phase III trial of Generex Oral-lyn(TM)

at 39 clinical sites worldwide. The Company is also developing

MetControl(TM) gum to avoid some of the adverse side effects associated

with generic metformin tablets. This product candidate could have a shorter

path to commercialization as metformin is already an established standard

of care for Type 2 diabetes. Generex's wholly owned subsidiary, Antigen

Express, Inc., develops prophylactic, immunotherapeutic, and diagnostic

candidates through proprietary platform technologies that modulate the

immune system to elicit specific responses. Antigen Express's most advanced

compound is a breast cancer vaccine in Phase II trials with the U.S.

Military Cancer Institute's Clinical Trials Group. In August 2008, Generex

began enrolling patients in a Phase I breast and ovarian cancer trial using

two immunotherapeutic vaccines designed to function in concert.

    About Crystal Research Associates, LLC



    Crystal Research Associates, LLC is an independent research firm that

provides institutional-quality, fee-based research to small and mid-cap

companies. Crystal Research Associates' unique and novel product, the

Executive Informational Overview(R) (EIO(R)), is free of investment

ratings, target prices, and forward-looking financial models. The EIO(R)

presents a crystal clear, detailed report on a company (public or private)

in a manner that is easily understood by the Wall Street financial

community. The EIO(R) details a company's product/technology/service

offerings, market size(s), key intellectual property, leadership, growth

strategy, competition, risks, audited financial statements, key events, and

other such fundamental information. Crystal Research Associates has offices

in New York City and Delray Beach. Crystal Research Associates has been

compensated by the Company in cash of forty thousand U.S. dollars for its

services in creating the base report, for updates, and for printing costs.



    Forward-Looking Safe Harbor Statement



    Statements in this news release regarding future financial and

operating results, potential applications of the Company's technology,

opportunities for the Company, and any other statements about the future

expectations, beliefs, goals, plans, or prospects expressed constitute

forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. Any statements that are not statements of

historical fact (including statements containing the words "will,"

"believes," "plans," "anticipates," "expects," "estimates," and similar

expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause actual results or

events to differ materially from those indicated by such forward-looking

statements including, limited operating history, need for future capital,

and economic conditions generally. Additional information on potential

factors that could affect results and other risks and uncertainties are

detailed from time to time in the Company's periodic reports.



    These statements, and other forward-looking statements, are not

guarantees of future performance and involve risks and uncertainties.

Crystal Research Associates assumes no obligation to update any of the

forward-looking statements in this release.